P/B
0,5
Seer
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
$107.7M
Market Cap • 9/11/2026
2017
(9 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
7,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4
EPS
—
Market Cap
Market Cap
107,7M
EV
-22,8M
EV/Revenue
-1,6
EV/EBITDA
0,4
EV/EBIT
0,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
4,3%
Total Yield
4,3%
Payout
0%
Retained Earnings
-499,7M
Profitability
Gross Margin
47,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
264,1%
Capex/Revenue
6%
Capex/D&A
14,3%
Capex/OCF
-2%
SBC/OCF
—
% PPE
12,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
51,1%
CAGR Op. Income 5Y
5,3%
CAGR Net Income 5Y
4,6%
CAGR EPS 5Y
-8,3%
CAGR OCF 5Y
3,7%
Leverage
N.D./EBITDA
2
Debt/Equity
0%
Current Ratio
14,7
Quick Ratio
13,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!